从分子靶向药物看内科肿瘤学的发展方向
摘要
人类已经迈进了二十一世纪的第九个年头．在科技高速发展的今天，人们企盼能否在本世纪初或中叶使恶性肿瘤的发病率和病死率有大幅度的下降。纵观肿瘤内科治疗的发展，虽然它与千岁老翁的手术治疗及百岁老人的放射治疗相比只是个仅50余岁的青年，但其发展速度、影响范围、对人类寿命的影响，均是前两者所不能项背的。但是，肿瘤内科治疗毁誉掺半的现状使人们不禁产生疑虑：内科治疗能否担此大任？
出处
《实用医药杂志》
2008年第1期1-2,共2页
Practical Journal of Medicine & Pharmacy
参考文献9
-
1Campiglio M,Locatelli A,Olgiati C,et al.Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.J Cell Physiol,2004,198(2):259.
-
2Janmaat ML,Kruyt FA,Rodriguez JA,et al.Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells:limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.Clin Cancer Res,2003,9(6):2316.
-
3Kanrarjian HM,Cortes JE,O'Brien S,et al.Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.Blood,2004,104(7):1979.
-
4Demetri GD,vonMehren M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med,2002,347(7):472.
-
5Geyer CE,Forster J,Lindquist D,et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer.N Engl J Med,2006,355(26):2733.
-
6Escudier B.Presented at:ECCO; October 30-November 3,2005; Paris,France.
-
7Llover J,Ricci S,Mazzaferro V,et al.Randomized phase Ⅲ trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC).J Clin Oncol,2007,25(18 suppl):LBA1.
-
8Vermorken J,Mesia R,Vega V,et al.Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy.Results of a randomized phase Ⅲ (EXTREME)study.J Clin Oncol,2007,25(18 suppl):6091.
-
9Lippman SM,Haymach JV.The convergent development of molecular-targeted drugs for cancer treatment and prevention.Clin Cancer Res,2007,13(14):4035.
-
1王肇炎.第13届亚太癌症会议内科肿瘤学的进展[J].中国肿瘤,1997,6(4):22-23. 被引量：3
-
2张百红,岳红云.肿瘤的内科治疗新策略[J].肿瘤,2016,36(9):1065-1069.
-
3曹缵孙,石一复.子宫肌瘤治疗展望[J].国外医学（妇幼保健分册）,2001,12(1):1-2. 被引量：5
-
4廉晓宇,牛广宇.脑胶质瘤治疗展望[J].黑龙江医药科学,2009,32(2):69-69. 被引量：3
-
5任大力,陈启龙.胰腺癌介入治疗展望[J].现代肿瘤医学,2009,17(9):1820-1822. 被引量：3
-
6周舒,艾君,路睿.肿瘤干细胞治疗展望[J].九江医学,2009,24(4):84-86.
-
7王玉瑾,张煦,杨国嵘,李军.视网膜母细胞瘤综合治疗及分子靶向治疗展望[J].中国中医药咨讯,2011,3(17):48-48.
-
8林莉.DC疫苗与宫颈癌治疗展望[J].中华医学写作杂志,2004,11(20):1784-1786.
-
9王肇炎.新世纪肿瘤化疗的趋势[J].抗癌,2004(1):45-46.
-
10周勤.肿瘤细胞逆转实验与肿瘤治疗展望[J].医学理论与实践,1994,7(9):21-22.
